Wanjun Zhang was named Chief Financial Officer of Curanex Pharmaceuticals Inc, succeeding Haiyan Yang, effective January 1, 2026. As of November 14, 2026, Curanex Pharmaceuticals Inc has reported 2 leadership change filings to the SEC under Item 5.02 of Form 8-K, from January 5, 2026 to March 6, 2026, naming 1 appointment and 1 departure (Form 8-K, January 5, 2026).
29 companies changed executives this week, 1 had other signals.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| ONITY GROUP INC. | announced the departure of its Chief Investment Officer | |
| Adicet Bio, Inc. | announced the departure of its Director | |
| MAMMOTH ENERGY SERVICES, INC. | announced the departure of its Chief Operating Officer | |
| CERENOME, INC. | named a new Director | |
| Cohen & Co Inc. | named a new Chief Executive Officer |
Sell to companies like Curanex Pharmaceuticals Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Curanex Pharmaceuticals Inc reported changes in 2 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-01-05 to 2026-03-06. They name 2 people, with 1 appointment and 1 departure. Every row below is cited to the filing it comes from, and this page adds each new change as Curanex Pharmaceuticals Inc files it.
Also on the record for Curanex Pharmaceuticals Inc
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| August 26, 2025 | IPO filing, Form 424B4 | $4 a share | IPO filings | Source |
| August 26, 2025 | IPO filing, Form 424B4 | $4 a share | IPO filings | Source |
| July 18, 2025 | IPO filing, Form S-1/A | $4 to $6 a share | IPO filings | Source |
| July 1, 2025 | IPO filing, Form S-1/A | $4 to $6 a share | IPO filings | Source |
| March 17, 2025 | IPO filing, Form S-1/A | $4 to $6 a share | IPO filings | Source |
| February 14, 2025 | IPO filing, Form S-1/A | $4 to $6 a share | IPO filings | Source |
| November 27, 2024 | IPO filing, Form S-1/A | $4 to $6 a share | IPO filings | Source |
| November 1, 2024 | IPO filing, Form S-1/A | $4 to $6 a share | IPO filings | Source |
| October 16, 2024 | IPO filing, Form S-1 | $4 to $6 a share | IPO filings | Source |
Selling to them or working with them? See who runs Curanex Pharmaceuticals Inc now and the warning signs.
Free to see. No signup.
Watch Curanex Pharmaceuticals Inc
Get an email when Curanex Pharmaceuticals Inc files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Curanex Pharmaceuticals Inc?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Curanex Pharmaceuticals Inc: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Curanex Pharmaceuticals Inc covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
11 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-03-06 | Reported | not named in the filing | 8-K, 2026-03-06 | ||
| 2026-01-05 | Out | Chief Financial Officer | 8-K, 2026-01-05 | ||
| 2026-01-05 | In | Chief Financial Officer | 2026-01-01 | 8-K, 2026-01-05 |
Why did they leave? What the filings say
For each named departure below, the sentence from the company's own filing that gives a reason, word for word. Where a filing gives none, it says so here; nothing is inferred.
- Haiyan Yang, Chief Financial Officer (filed 2026-01-05):
Ms. Yang's decision to resign was not due to any disagreement relating to the Company's operations, policies or practices.
Who leads Curanex Pharmaceuticals Inc, as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Chief Financial Officer: Haiyan Yang, departure reported (filed 2026-01-05). No successor is named in these filings.
New leaders reset buying decisions — get the Full Report on Curanex Pharmaceuticals Inc: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Chief Financial Officer at Curanex Pharmaceuticals Inc, with the record behind each one.
Find candidates like Chief Financial Officer at Curanex Pharmaceuticals IncEvery change, in the filing's words
Reported
The CEO Agreement relates to the continuation of Mr. Liu's services as Chief Executive Officer and President of the Company since his appointment to these positions in February 2024, and requires Mr. Liu to provide the services and responsibilities consistent with the position of chief executive officer and president of a publicly listed company, including taking overall responsibility for the Company's management, corporate strategy, research and development oversight, clinical and regulatory coordination, capital markets activities, and execution of the Company's business, subject at all tim
- CEO Employment Agreement On March 2, 2026, Curanex Pharmaceuticals Inc (the "Company") entered into an executive employment agreement with Mr. Jun Liu, the Chief Executive Officer and President of the Company, effective March 1, 2026 (the "CEO Agreement").
- The term of the CEO Agreement begins on the Effective Date and ends on the fourth anniversary of the Effective Date, until terminated earlier by the parties under the terms of the CEO Agreement.
- It may be renewed upon the same terms and conditions for successive one-year periods, upon mutual consent of the parties.
- If the CEO Agreement is terminated due to Mr. Liu's death, his beneficiary shall receive any salary, benefits and reimbursements that would otherwise have been payable to Mr. Liu as of the date of his death.
- If the CEO Agreement is terminated due to Mr. Liu's disability, upon determination that a disability exists, after consultation with a qualified, independent physician, Mr. Liu shall be entitled to receive any amounts of salary earned, accrued and owing but not yet paid and any benefits accrued and due under any applicable benefit plans and programs of the Company.
Departing: Haiyan Yang, Chief Financial Officer
On December 31, 2025, Haiyan Yang informed Curanex Pharmaceuticals Inc, a Nevada corporation (the "Company") of her resignation as Chief Financial Officer and Treasurer of the Company, effective immediately.
Appointed: Wanjun Zhang, Chief Financial Officer, effective 2026-01-01
On December 31, 2025, in connection with the resignation of Ms. Yang, the Company appointed Wanjun Zhang as Chief Financial Officer and Treasurer of the Company, effective January 1, 2026.
- Mr. Zhang, 52, has over 20 years of financial and accounting related experience, specializing in financial reporting, compliance, and business strategy.
- Before joining Curanex, from July 2020, he provided financial consulting and accounting services to small and medium size companies, focusing on financial reporting, compliance and business strategy.
- In connection with Mr. Zhang's appointment, on December 31, 2025, the Company entered with him into a consulting agreement (the "CFO Agreement"), for the initial term of two (2) years from January 1, 2026 (the "Effective Date").
Tools for this story
Each opens in a new tab, filled in for Curanex Pharmaceuticals Inc. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.
